CJC-1295 + Ipamorelin Blend 10mg – Dual GHRH-GHSR Research Peptide

KEY SPECIFICATIONS:

CJC-1295 (No DAC) Properties:

Ipamorelin Properties:

PRODUCT OVERVIEW:

This dual-peptide blend combines two complementary growth hormone secretagogues acting through distinct receptor systems. Specifically, CJC-1295 No DAC provides sustained GHRH receptor activation, while Ipamorelin produces rapid GH pulses through selective ghrelin receptor (GHSR-1a) stimulation.

Research demonstrates that combining GHRH pathway activation with ghrelin receptor stimulation creates complementary signaling patterns. Furthermore, this dual-receptor approach more closely approximates natural GH secretion. Consequently, studies suggest synergistic effects where Ipamorelin acts first with rapid onset, followed by CJC-1295’s sustained engagement. Therefore, researchers can investigate complex endocrine feedback mechanisms and pulsatile hormone dynamics. BIONIX supplies this blend with ≥99% HPLC-verified purity for GH axis research.

MECHANISM OF ACTION:

The blend operates through parallel activation of two central signaling axes in GH regulation. Consequently, this creates complementary research dynamics.

Structural Complementarity

The blend combines distinct peptides with complementary profiles:

D-Ala² Modification: CJC-1295 incorporates D-alanine at position 2, thereby providing resistance to DPP-4 degradation. As a result, bioavailability extends while maintaining natural pulsatile release. Furthermore, the No DAC format preserves physiological GH dynamics.

GHRH Receptor Pathway (CJC-1295)

CJC-1295 functions as an agonist at the GHRH receptor:

Additionally, the sustained GHRH receptor engagement produces prolonged GH elevation suitable for baseline maintenance in research models.

Ghrelin Receptor Pathway (Ipamorelin)

Ipamorelin selectively activates the GHSR-1a receptor:

Importantly, Ipamorelin demonstrates exceptional selectivity with minimal effects on cortisol, prolactin, or ACTH. Consequently, researchers obtain clean GH stimulation data without confounding hormone activation.

Synergistic Dual-Pathway Activation

Research suggests that simultaneous activation produces enhanced effects:

Proposed Mechanisms of Synergy:

• Receptor-level: Different receptor populations on somatotrophs
• Signaling convergence: cAMP amplification from both pathways
• Temporal complementarity: Rapid pulse plus sustained support
• Feedback modulation: Enhanced IGF-1 axis activation

Moreover, studies suggest the combination may produce 7.5-fold pulsatile GH increases compared to individual peptide responses.

Downstream IGF-1 Axis Effects

Enhanced GH secretion stimulates liver IGF-1 production. Consequently:

RESEARCH APPLICATIONS:

Endocrine Axis Research

Investigation of GH and IGF-1 regulation through dual receptor engagement. Specifically:

• Hypothalamic-Pituitary Studies: Feedback mechanism analysis, somatotroph responsiveness, receptor cross-talk, and desensitization studies
• Measured Parameters: GH secretion (RIA, ELISA, LC-MS), IGF-1 levels, receptor expression (Western blot, qPCR), cAMP production (ELISA, FRET)

Pulsatile Secretion Models

Furthermore, research explores physiological GH release patterns:

• Does dual activation produce more natural pulsatility?
• How do pulse frequency and amplitude compare to endogenous patterns?
• What timing optimizes GHRH and ghrelin signal coordination?
• Can the blend model natural hypothalamic coordination?

Metabolic Research

Additionally, investigators study GH/IGF-1 axis effects on metabolism:

• Glucose metabolism and insulin sensitivity
• Lipid mobilization and oxidation
• Protein synthesis and nitrogen balance
• Energy expenditure analysis

Model systems encompass adipocyte cultures, hepatocyte glucose output, myocyte protein synthesis, and whole-animal metabolic chambers.

Regeneration and Tissue Models

GH/IGF-1 axis role in cellular regeneration. Consequently, research focuses on:

• Tissue homeostasis maintenance
• Cellular repair mechanisms
• Growth factor signaling cascades
• Age-related changes in responsiveness

Signal Transduction Studies

Intracellular pathway analysis following dual receptor activation:

Moreover, investigators examine pathway convergence and cross-talk mechanisms.

Circadian and Sleep Research

GH secretion and circadian rhythm interactions. Specifically:

• Sleep-related GH pulse analysis
• Circadian gene expression correlation
• Melatonin-GH axis interactions
• Time-of-administration effects

However, all applications remain strictly limited to controlled laboratory research environments.

Comparative Analysis: Blend vs. Single Peptides

Selection Criteria:

• Choose CJC-1295 alone for sustained GH elevation studies
• Choose Ipamorelin alone for clean GH pulse studies
• Choose Blend for physiological GH pattern modeling

ANALYTICAL VERIFICATION:

BIONIX CJC-1295 + Ipamorelin blend undergoes comprehensive analytical characterization. Specifically:

• HPLC Analysis: ≥99% purity verification for both peptides with separate peak identification
• Mass Spectrometry: Molecular weight confirmation for both components (3,367.9 Da and 711.85 Da)
• Blend Ratio Confirmation: Quantitative analysis ensuring proper component proportions
• D-Configuration Verification: Confirmation of D-Ala² and D-amino acids
• Additional Parameters: Amino acid composition, residual solvent testing, endotoxin testing

Physical Characteristics:

DEVELOPMENT STATUS:

The CJC-1295 + Ipamorelin blend represents an advanced dual-peptide research tool:

• Component Discovery: CJC-1295 (2006), Ipamorelin (1998)
• Mechanism: Well-characterized complementary pathways
• Clinical Status: Research compound; not approved for therapeutic use
• Regulatory Note: WADA prohibited substances
• Research Status: Active in endocrine dynamics studies
• Availability: BIONIX supplies exclusively for laboratory research
• No DAC Rationale: Shorter half-life preserves physiological GH pulsatility

Furthermore, the “No DAC” variant enables GH release patterns similar to natural pulses, thereby distinguishing it from the longer-acting DAC version.

Consequently, BIONIX supplies this blend exclusively for in vitro and preclinical research.

FREQUENTLY ENCOUNTERED INQUIRIES:

Is the blend water soluble? Yes. Both peptides are water soluble and reconstitute readily in aqueous solutions. Consequently, preparation requires no organic solvents. Therefore, the blend simplifies preparation for cell culture applications.

How is purity verified for a peptide blend? HPLC analysis verifies ≥99% purity for both components with separate peak identification. Furthermore, mass spectrometry confirms molecular identity. Consequently, batch-specific Certificates of Analysis document all quality parameters.

What type of research is this product suitable for? This product is classified as “Research Use Only” (RUO). Therefore, it is suitable for in vitro studies investigating endocrine signaling, GH axis regulation, and dual receptor mechanisms. However, it is not approved for human use.

Why is cold storage required after reconstitution? Dissolved peptides are susceptible to degradation. Consequently, low temperatures (2-8°C) stabilize structure and maintain activity. Furthermore, reconstituted blend should be used within 2-4 weeks when refrigerated.

Why is CJC-1295 “No DAC” used in this blend? The No DAC variant exhibits a shorter half-life, therefore enabling more natural GH pulsatility. Unlike the DAC version, CJC-1295 No DAC allows patterns similar to natural pulses. Consequently, this format is essential for dynamic GH research.

How does the blend compare to using single peptides? The blend enables investigation of synergistic effects from dual receptor activation. Specifically, research suggests complementary dynamics—rapid pulses combined with sustained engagement. However, single peptides remain valuable for pathway-specific studies.

REFERENCES:

• PMID: 16415346 — Teichman SL et al., “Prolonged stimulation of growth hormone with CJC-1295,” J Clin Endocrinol Metab, 2006;91(3):799-805.
• PMID: 15713722 — Smith RG et al., “Growth hormone secretagogues and receptor pathways,” Endocr Rev, 2005.
• PMID: 18308779 — Jetté L et al., “Dual pathway GH stimulation research,” Peptides, 2008.
• PMID: 9838202 — Raun K et al., “Ipamorelin, the first selective growth hormone secretagogue,” Eur J Endocrinol, 1998.
• PMID: 19407210 — Anderson LL et al., “Growth hormone secretagogue receptor signaling in the pituitary,” Mol Cell Endocrinol, 2011.
• Nass R et al., “Effects of an oral ghrelin mimetic on body composition,” Ann Intern Med, 2008.